Industry
Biotechnology
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Loading...
Open
18.50
Mkt cap
1.2B
Volume
427K
High
18.61
P/E Ratio
23.23
52-wk high
21.28
Low
18.35
Div yield
N/A
52-wk low
14.33
Portfolio Pulse from
November 26, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 5:10 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 9:05 pm
Portfolio Pulse from Benzinga Newsdesk
July 30, 2024 | 2:02 pm
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 5:38 pm
Portfolio Pulse from Vandana Singh
June 18, 2024 | 5:44 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
May 20, 2024 | 4:40 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 9:20 pm
Portfolio Pulse from Benzinga Newsdesk
April 24, 2024 | 11:12 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.